Aminologics

At a glance

Aminologics filed 29 disclosures in the last 12 months, including 7 insider and 5 5% holder. The most recent key filing was on Oct 8.

Revenue for 2025 was ₩22B, up 31.1% on 2024. Operating margin was 16.3% against -12.8% a year earlier. Debt was 50% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩13.6B and operating profit of ₩2.6B.

The 2025 annual report lists 41 employees with an average tenure of 5.9 years and average pay of ₩69.3M. Its 5 directors and auditors were paid ₩84M each on average. It paid no cash dividend for 2025. (주)삼오제약 and related parties held 31.81% at year end.

From the 2025 annual report

Staff: 41 (28 men, 13 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩2.8B. Directors and auditors: 5, paid ₩418M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)삼오제약 holds 30.50%; with 3 related parties the group holds 31.81% of common shares at year end.

Auditor: 안진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary